Company Performance Metrics
- William McCroskey: President and CEO
NueVue Solutions, Inc. (NVS) is developing a new platform technology called Theranostic Hybrid Spectral Molecular Imaging (THSMI). This technology is both an therapeutic technology and imaging technology utilizing custom designed functional nano particles coupled with new spectral molecular imaging technology to target and track cells in the body.
We are focusing on medical applications of Orthopedics, Stroke, and Cancers. NVS is doing a Series A of $4M to developed Theranostic Hybrid Spectral Molecular Imaging System and Targeted Nano particles for Stroke therapy, Orthopedic infections, and for lung, breast, colon, and prostate cancer therapy. Recently NVS received an Innovation fund Grant for it’s novel technology and market application. The Series A will enable NVS to build R&D Clinical prototypes for early adopter validation of the Theranostic Hybrid Spectral Molecular Imaging and functionalized nano particle contrast and therapy agents. With these proof of concepts, NVS will aggressively develop early adopter sales and market acceptance to build a $60M - $80M rapidly growing business by 2020 in a $200B Theranostics market. NVS’s potential exits are to larger drug and medical device companies.
